Literature DB >> 21459819

Substantially reduced pre-patent parasite multiplication rates are associated with naturally acquired immunity to Plasmodium falciparum.

A D Douglas1, L Andrews, S J Draper, K Bojang, P Milligan, S C Gilbert, E B Imoukhuede, A V S Hill.   

Abstract

Naturally acquired immunity to Plasmodium falciparum's asexual blood stage reduces parasite multiplication at microscopically detectable densities. The effect of natural immunity on initial prepatent parasite multiplication during the period following a new infection has been uncertain, contributing to doubt regarding the utility of experimental challenge models for blood-stage vaccine trials. Here we present data revealing that parasite multiplication rates during the initial prepatent period in semi-immune Gambian adults are substantially lower than in malaria-naive participants. This supports the view that a blood-stage vaccine capable of emulating the disease-reducing effect of natural immunity could achieve a detectable effect during the prepatent period.

Entities:  

Mesh:

Year:  2011        PMID: 21459819      PMCID: PMC3398130          DOI: 10.1093/infdis/jir033

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  12 in total

Review 1.  Blood stage vaccines for Plasmodium falciparum: current status and the way forward.

Authors:  Ruth D Ellis; Issaka Sagara; Ogobara Doumbo; Yimin Wu
Journal:  Hum Vaccin       Date:  2010-08

2.  Lengthy antimalarial activity of atovaquone in human plasma following atovaquone-proguanil administration.

Authors:  M D Edstein; B M Kotecka; K L Anderson; D J Pombo; D E Kyle; K H Rieckmann; M F Good
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

3.  Blood-stage challenge for malaria vaccine efficacy trials: a pilot study with discussion of safety and potential value.

Authors:  Frances Sanderson; Laura Andrews; Alexander D Douglas; Angela Hunt-Cooke; Philip Bejon; Adrian V S Hill
Journal:  Am J Trop Med Hyg       Date:  2008-06       Impact factor: 2.345

Review 4.  Prime-boost vectored malaria vaccines: progress and prospects.

Authors:  Adrian V S Hill; Arturo Reyes-Sandoval; Geraldine O'Hara; Katie Ewer; Alison Lawrie; Anna Goodman; Alfredo Nicosia; Antonella Folgori; Stefano Colloca; Riccardo Cortese; Sarah C Gilbert; Simon J Draper
Journal:  Hum Vaccin       Date:  2010-01-18

Review 5.  Immunity to malaria: more questions than answers.

Authors:  Jean Langhorne; Francis M Ndungu; Anne-Marit Sponaas; Kevin Marsh
Journal:  Nat Immunol       Date:  2008-07       Impact factor: 25.606

6.  A hypothesis about the chronicity of malaria infection.

Authors:  P Druilhe; J L Pérignon
Journal:  Parasitol Today       Date:  1997-09

7.  Malaria: even more chronic in nature than previously thought; evidence for subpatent parasitaemia detectable by the polymerase chain reaction.

Authors:  E Bottius; A Guanzirolli; J F Trape; C Rogier; L Konate; P Druilhe
Journal:  Trans R Soc Trop Med Hyg       Date:  1996 Jan-Feb       Impact factor: 2.184

8.  Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites.

Authors:  Philip Bejon; Laura Andrews; Rikke F Andersen; Susanna Dunachie; Daniel Webster; Michael Walther; Sarah C Gilbert; Tim Peto; Adrian V S Hill
Journal:  J Infect Dis       Date:  2005-01-07       Impact factor: 5.226

9.  Low-level malaria infections detected by a sensitive polymerase chain reaction assay and use of this technique in the evaluation of malaria vaccines in an endemic area.

Authors:  Egeruan B Imoukhuede; Laura Andrews; Paul Milligan; Tamara Berthoud; Kalifa Bojang; Davis Nwakanma; Jamila Ismaili; Caroline Buckee; Fanta Njie; Saikou Keita; Maimuna Sowe; Trudie Lang; Sarah C Gilbert; Brian M Greenwood; Adrian V S Hill
Journal:  Am J Trop Med Hyg       Date:  2007-03       Impact factor: 2.345

10.  Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials.

Authors:  Laura Andrews; Rikke F Andersen; Daniel Webster; Susanna Dunachie; R Michael Walther; Philip Bejon; Angela Hunt-Cooke; Gillian Bergson; Frances Sanderson; Adrian V S Hill; Sarah C Gilbert
Journal:  Am J Trop Med Hyg       Date:  2005-07       Impact factor: 2.345

View more
  24 in total

Review 1.  Controlled human blood stage malaria infection: current status and potential applications.

Authors:  Christopher J A Duncan; Simon J Draper
Journal:  Am J Trop Med Hyg       Date:  2012-04       Impact factor: 2.345

2.  Density-dependent blood stage Plasmodium falciparum suppresses malaria super-infection in a malaria holoendemic population.

Authors:  Mykola Pinkevych; Janka Petravic; Kiprotich Chelimo; John Vulule; James W Kazura; Ann M Moormann; Miles P Davenport
Journal:  Am J Trop Med Hyg       Date:  2013-09-09       Impact factor: 2.345

Review 3.  Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy?

Authors:  Christopher J A Duncan; Adrian V S Hill; Ruth D Ellis
Journal:  Hum Vaccin Immunother       Date:  2012-04-20       Impact factor: 3.452

4.  Antibody and T-cell responses associated with experimental human malaria infection or vaccination show limited relationships.

Authors:  Karen M Walker; Shinji Okitsu; David W Porter; Christopher Duncan; Mario Amacker; Gerd Pluschke; David R Cavanagh; Adrian V S Hill; Stephen M Todryk
Journal:  Immunology       Date:  2015-05       Impact factor: 7.397

5.  Erythrocyte-binding antigens of Plasmodium falciparum are targets of human inhibitory antibodies and function to evade naturally acquired immunity.

Authors:  Kristina E M Persson; Freya J I Fowkes; Fiona J McCallum; Nimmo Gicheru; Linda Reiling; Jack S Richards; Danny W Wilson; Sash Lopaticki; Alan F Cowman; Kevin Marsh; James G Beeson
Journal:  J Immunol       Date:  2013-06-17       Impact factor: 5.422

6.  Decreased growth rate of P. falciparum blood stage parasitemia with age in a holoendemic population.

Authors:  Mykola Pinkevych; Janka Petravic; Kiprotich Chelimo; John Vulule; James W Kazura; Ann M Moormann; Miles P Davenport
Journal:  J Infect Dis       Date:  2013-11-21       Impact factor: 5.226

7.  Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults.

Authors:  Caroline Ogwang; Domtila Kimani; Britta C Urban; Adrian V S Hill; Philip Bejon; Nick J Edwards; Rachel Roberts; Jedidah Mwacharo; Georgina Bowyer; Carly Bliss; Susanne H Hodgson; Patricia Njuguna; Nicola K Viebig; Alfredo Nicosia; Evelyn Gitau; Sandy Douglas; Joe Illingworth; Kevin Marsh; Alison Lawrie; Egeruan B Imoukhuede; Katie Ewer
Journal:  Sci Transl Med       Date:  2015-05-06       Impact factor: 17.956

Review 8.  Asymptomatic malaria infections: detectability, transmissibility and public health relevance.

Authors:  Teun Bousema; Lucy Okell; Ingrid Felger; Chris Drakeley
Journal:  Nat Rev Microbiol       Date:  2014-10-20       Impact factor: 60.633

9.  Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01.

Authors:  Ruth O Payne; Kathryn H Milne; Sean C Elias; Nick J Edwards; Alexander D Douglas; Rebecca E Brown; Sarah E Silk; Sumi Biswas; Kazutoyo Miura; Rachel Roberts; Thomas W Rampling; Navin Venkatraman; Susanne H Hodgson; Geneviève M Labbé; Fenella D Halstead; Ian D Poulton; Fay L Nugent; Hans de Graaf; Priya Sukhtankar; Nicola C Williams; Christian F Ockenhouse; April K Kathcart; Aziz N Qabar; Norman C Waters; Lorraine A Soisson; Ashley J Birkett; Graham S Cooke; Saul N Faust; Colleen Woods; Karen Ivinson; James S McCarthy; Carter L Diggs; Johan Vekemans; Carole A Long; Adrian V S Hill; Alison M Lawrie; Sheetij Dutta; Simon J Draper
Journal:  J Infect Dis       Date:  2016-02-04       Impact factor: 5.226

10.  Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination.

Authors:  Angela M Minassian; Sarah E Silk; Jordan R Barrett; Carolyn M Nielsen; Kazutoyo Miura; Ababacar Diouf; Carolin Loos; Jonathan K Fallon; Ashlin R Michell; Michael T White; Nick J Edwards; Ian D Poulton; Celia H Mitton; Ruth O Payne; Michael Marks; Hector Maxwell-Scott; Antonio Querol-Rubiera; Karen Bisnauthsing; Rahul Batra; Tatiana Ogrina; Nathan J Brendish; Yrene Themistocleous; Thomas A Rawlinson; Katherine J Ellis; Doris Quinkert; Megan Baker; Raquel Lopez Ramon; Fernando Ramos Lopez; Lea Barfod; Pedro M Folegatti; Daniel Silman; Mehreen Datoo; Iona J Taylor; Jing Jin; David Pulido; Alexander D Douglas; Willem A de Jongh; Robert Smith; Eleanor Berrie; Amy R Noe; Carter L Diggs; Lorraine A Soisson; Rebecca Ashfield; Saul N Faust; Anna L Goodman; Alison M Lawrie; Fay L Nugent; Galit Alter; Carole A Long; Simon J Draper
Journal:  Med (N Y)       Date:  2021-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.